Cholecystokinin.
1. CCK-peptides are distributed throughout the whole brain with the exception of the cerebellum. 2. There is strong evidence that they act as neuromodulators on the noradrenergic, opioid and mainly dopaminergic system. 3. CCK reduces food-intake. However, tolerance occurs, when chronically given. Thus, potential benefits in the treatment of obesity seem unlikely. 4. CCK increases threshold and tolerance to electrically and thermally induced cutaneous pain. CCK yields relief of pain in colic and ischaemic pain. 5. To date, results about CCK-content in CSF and post-mortem-brain in various psychiatric and neurological diseases related to the dopaminergic system are equivocal. 6. Treatment studies do not provide evidence for beneficial effects of CCK-peptides in schizophrenia.
Albus
M
M
Psychiatric Hospital, University of Munich, GFR.
D000818:Animals; D001921:Brain / Q000502:physiology; D002766:Cholecystokinin / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology; D004723:Endorphins / Q000502:physiology; D006801:Humans; D001523:Mental Disorders / Q000503:physiopathology; D009422:Nervous System Diseases / Q000503:physiopathology; D009638:Norepinephrine / Q000502:physiology; D010146:Pain / Q000503:physiopathology
D004723:Endorphins; D002766:Cholecystokinin; D004298:Dopamine; D009638:Norepinephrine